Professor of Medicine, Beth Israel Deaconess Medical Center
Oncology
Dr. Stephen A. Cannistra, MD
|
|
Give Review
Stephen Cannistra is an expert in the field of Oncology. He studied medicine at Warren Alpert Medical School of Brown University. Stephen Cannistra has written publications. He has 96 publications published with PubMed. The lastest publication is: 'BAD partly reverses paclitaxel resistance in human ovarian cancer cells.'
Publications
- Comparing Poly (ADP-Ribose) Polymerase Inhibitors With Standard Chemotherapy in BRCA-Mutated, Recurrent Ovarian Cancer: Lessons Learned From a Negative Trial.
- Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
- Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
- New Initiatives at Journal of Clinical Oncology.
- Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.
- Phase I studies of drug combinations.
- Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
- Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?
- Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
- Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal ...
- Phase II trials in journal of clinical oncology.
- Challenges and pitfalls of combining targeted agents in phase I studies.
- BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease.
- Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
- Performance of biopsies in clinical research.
- Gynecologic oncology or medical oncology: what's in a name?
- Intraperitoneal chemotherapy comes of age.
- Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
- Advances in the management of epithelial ovarian cancer.
- Cancer of the ovary.
- Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
- A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
- The ethics of early stopping rules: who is protecting whom?
- Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
- Progress in the management of gynecologic cancer: consensus summary statement.
- Granulosa cell tumor of the ovary.
- Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?
- Gene-expression profiling in epithelial ovarian cancer.
- Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.
- IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.
- Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model.
- Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity.
- Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced e...
- Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro.
- In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.
- Back to the future: multiagent chemotherapy in ovarian cancer revisited.
- BAD partly reverses paclitaxel resistance in human ovarian cancer cells.
- Functional heterogeneity of CD44 molecules in ovarian cancer cell lines.
- BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.
- BAX protein expression and clinical outcome in epithelial ovarian cancer.
- Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin.
- "Cancer defeated": not if, but when--introducing the Biology of Neoplasia series.
- Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells.
- BRCA1 mutations and survival in women with ovarian cancer.
- In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantat...
- BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.
- Absence of constitutive EGF receptor activation in ovarian cancer cell lines.
- Estrogen receptor expression is a common feature of ovarian borderline tumors.
- Location of BRCA1 in human breast and ovarian cancer cells.
- Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine.
- Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.
- 111In-CYT-103 immunoscintigraphy in ovarian cancer.
- Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
- Paclitaxel in ovarian cancer: how can we make it better?
- Interval cytoreduction in ovarian cancer.
- CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors.
- Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer.
- Vascular cell adhesion molecule-1 expressed by peritoneal mesothelium partly mediates the binding of activated human T lymphocytes.
- Differential expression of HLA-DR antigens in subsets of human CFU-GM.
- Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells.
- Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells.
- Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors.
- Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistan...
- Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes.
- Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism.
- Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor.
- Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes.
- T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro.
- Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
- Regulation of the production and function of granulocytes and monocytes.
- Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo.
- Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.
- Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis ...
- Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 rec...
- Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2.
- In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells.
- Association between clonogenic cell growth and clinical risk group in B-cell chronic lymphocytic leukemia.
- Cellular interaction regulating the production of colony-stimulating factors.
- Chronic myelogenous leukemia as a model for the genetic basis of cancer.
- Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cyto...
- Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells.
- The biology of GM-CSF: regulation of production and interaction with its receptor.
- Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells.
- Why should the clonogenic cell assay be prognostically important in ovarian cancer?
- Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopo...
- Growth regulation of malignant clonogenic cells in acute myeloid leukemia.
- Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
- Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies.
- Characterization of adhesion molecules on human myeloma cell lines.
- Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I.
- A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a co...
- Diagnostic dilemmas in oncology: case 2. Dermatomyositis and ovarian cancer.
- Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcin...
- Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian c...
- When is a "prognostic factor" really prognostic?
Schools
The Warren Alpert Medical School Of Brown University
Johns Hopkins Hospital
Dana Farber Canc Institute
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Johns Hopkins University -
Warren Alpert Medical School of Brown University
Hospital
-
Beth Israel Deaconess Medical Center
Helpful Reviews
Similar Doctors
|
|
Sheheryar K. Kabraji, MB CHB
 This Doctor is OpenDoctor Recommended.
|
|
|
Irving H. Goldberg
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruth M. Ruprecht, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Philip W. Kantoff, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Nicole G. Chau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory J. Britt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eliezer M. VanAllen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julia H. Hayes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas A. Abrams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren J. Oshry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marjory Charlot, MD
This Doctor is OpenDoctor Recommended.
|